Search company, investor...

Founded Year



Acq - P2P | Acquired

Total Raised




About Iomai Corporation

Iomai Corporation is developing vaccines and immune system stimulants delivered through needle-free transcutaneous immunization

Headquarters Location

20 Firstfield Road Suite 250

Gaithersburg, Maryland, 20878,

United States




Latest Iomai Corporation News

08:00 EDT Codagenix Announces Appointment of Kimber Poffenberger, Ph.D., as Chief Strategy Officer

Mar 28, 2023

News provided by Share this article Share this article FARMINGDALE, N.Y., March 28, 2023 /PRNewswire/ -- Codagenix Inc., a clinical-stage synthetic biology company with a rational virus design platform for live-attenuated viral vaccines and immuno-oncology therapeutics, today announced that Kimber Poffenberger, Ph.D., has been appointed Chief Strategy Officer. Kimber Poffenberger, Ph.D., Chief Strategy Officer, Codagenix "We are excited to welcome Kimber to Codagenix. With her distinguished track record of driving global vaccine development and history of successfully leading cross-business strategic teams, she will provide an invaluable perspective to our organization as we continue to develop our deep clinical pipeline of live attenuated vaccines and cancer virotherapeutics," said J. Robert Coleman, Ph.D., M.B.A., Co-Founder and Chief Executive Officer of Codagenix. "Kimber brings extensive regulatory and product expertise, which will be critical as we work to bring our medicines to the patients who need them most." "I look forward to working alongside the Codagenix team as we build upon their innovative work in live attenuated virus design and development to take on the biggest threats in infectious diseases, cancer and animal health," said Dr. Poffenberger. "I am excited to help advance the Codagenix vaccine and oncology pipeline, which has the potential to address critical unmet needs in indications such as RSV, influenza, breast cancer and COVID-19." Dr. Poffenberger has over 20 years of strategic and regulatory leadership experience at pharma and biotech companies since her early career days in discovery research and FDA review. She most recently served as Principal Consultant at Poffenberger Regulatory Resources and prior to this role was Senior Vice President, Head of Global Regulatory Affairs at Alvotech. She has led regulatory affairs and product development teams supporting successful vaccines at all stages of development from discovery through commercial life cycle management as Vice President and Regional US Head, Global Regulatory Affairs at GSK Vaccines and as Executive Director, Global Vaccines Strategy at Merck. Dr. Poffenberger also held numerous leadership positions at Intercell, MedImmune, and Iomai Corporation. Dr. Poffenberger earned her Ph.D. in Microbiology from the University of Chicago, and her B.S. from Carnegie Mellon University. About Codagenix, Inc. Codagenix is a clinical-stage biotechnology company leading a new era of live vaccines and viral therapeutics. The company's breakthrough platform brings together live-attenuated virus design with cutting-edge codon deoptimization for powerful synthetic biology-based solutions to take on our biggest threats in infectious disease, cancer and animal health. Codagenix was founded based on technology developed in the laboratory of National Academy of Science member Dr. Eckard Wimmer at Stony Brook University; is supported by Adjuvant Capital, TopSpin Partners, and Euclidean Capital; and has ongoing research and license programs with various federal agencies. For more information, visit . Media Contact

Iomai Corporation Frequently Asked Questions (FAQ)

  • When was Iomai Corporation founded?

    Iomai Corporation was founded in 1997.

  • Where is Iomai Corporation's headquarters?

    Iomai Corporation's headquarters is located at 20 Firstfield Road, Gaithersburg.

  • What is Iomai Corporation's latest funding round?

    Iomai Corporation's latest funding round is Acq - P2P.

  • How much did Iomai Corporation raise?

    Iomai Corporation raised a total of $101.17M.

  • Who are the investors of Iomai Corporation?

    Investors of Iomai Corporation include Intercell, New Enterprise Associates, RA Capital Management, Red Abbey Venture Partners, UBS and 21 more.

  • Who are Iomai Corporation's competitors?

    Competitors of Iomai Corporation include ISA Pharmaceuticals, Zosano Pharma, Bellicum Pharmaceuticals, Immune Design, Vaxart and 7 more.


Compare Iomai Corporation to Competitors


Mucosis is a clinical-stage Dutch biotechnology company with a proprietary platform technology, Mimopath, on which it develops novel vaccines using various routes of administration including those that provide additional protection in the mucosa, the site where over 90% of pathogens enter the human body. Mucosis's lead product is SynGEM, a stabilized prefusion F protein recombinant vaccine to prevent RSV infection in various target groups. In addition, the company has developed PneuGEM, a vaccine to prevent diseases caused by pneumococcal bacteria and FluGEM, a vaccine to prevent influenza which served as a successful Mimopath platform proof of concept through human clinical testing.

ISA Pharmaceuticals

ISA Pharmaceuticals develops treatments for various cancers and infectious diseases. It focuses on the development of synthetic peptide vaccines that boost the immune system to recognize specific peptides associated with specific types of cancer and subsequently destroy the tumor cells. The company was founded in 2004 and is based in Oestgeest, Netherlands.


Vaxent has developed a StepNovA vaccine for Group A streptococcus

Lofarma S.p.A.

nnFor more than fifty years, the company have been plotting the route in Allergy medicine. The company have been leading generations of allergists to some of the most discoveries in this science:na vaccine by bronchial route, a vaccine by nasal route, the Methacholine Challenge Test, the Test Dose for foodstuff or additives allergy, and allergens adsorbed on single-use needles.

Savine Therapeutics

The focus of Savine Therapeutics is to develop and commercialise vaccines for prevention and treatment of diseases using it's Scrambled Antigen Vaccine (SAVINE) technology.  The technology was invented by researchers in the John Curtin School of Medical Research at the Australian National University.  Per the company, it enables production of vaccines suitable for a broad range of serious worldwide infectious diseases and cancers. See


Onyvax is developing new cancer therapies that harness the selective power of the immune system to seek out and destroy tumor cells. Onyvax's products specifically target cancer cells, increasing the likelihood that they will be effective while minimising side effects associated with many conventional treatments. These therapies can broadly be classed as therapeutic cancer vaccines. Onyvax's lead product is in clinical trials for the treatment of prostate cancer and is poised to enter the final stages of development. Onyvax is committed to the commercialisation of therapies that enhance survival while maintaining a high quality of life for patients. The Company is based in London and has collaborations with leading hospitals and other institutions throughout Europe and the US.


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.